Document Detail

Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects.
MedLine Citation:
PMID:  16434834     Owner:  NLM     Status:  MEDLINE    
Matrix metalloproteinases (MMPs) are involved in the regulation of the extracellular matrix (ECM) of the myocardium and thus the pathogenesis of vascular and cardiac hypertrophy. In this study, we investigated contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy (LVH) and diastolic dysfunction in hypertensive subjects. Hypertensive patients with (n = 27) and without LVH (n = 23) were included. All participants underwent a complete transthoracic echocardiographic examination, including recordings of the mitral annular early, late, systolic and diastolic velocities by Doppler imaging. Plasma concentrations of MMP-3 and MMP-9 were determined by the one-step sandwich enzyme immunoassay method. Plasma MMP-3 and MMP-9 concentrations were significantly higher in patients with LVH than those without LVH (2.4 +/- 1.2 vs 1.5 +/- 0.7 ng/ml, p = 0.006 and 5.2 +/- 2.8 vs 3.3 +/- 1.7 ng/ml, p = 0.003, respectively). MMP-3 and MMP-9 levels were also correlated with left ventricular posterior wall thickness and Doppler indices of diastolic dysfunction. Our findings have suggested that increased MMP levels may contribute to LVH and left ventricular diastolic dysfunction. Therefore, treatment of hypertension with MMP lowering drugs, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers, may have favorable effects on LVH and left ventricular diastolic dysfunction.
Mustafa Saglam; Osman Karakaya; Ali Metin Esen; Irfan Barutcu; Serkan Dogan; Yusuf Karavelioglu; Hekim Karapinar; Taylan Akgun; Ozlem Esen; Nihal Ozdemir; Sembol Turkmen; Cihangir Kaymaz
Related Documents :
10657594 - Right ventricular upregulation of the ca(2+) binding protein s100a1 in chronic pulmonar...
10918644 - Heart failure with normal systolic function.
9321744 - Is the absence of a normal nocturnal fall in blood pressure (nondipping) associated wit...
945164 - The influence of hypertrophy on myocardial function.
12441994 - Alterations in the molecular determinants of bladder compliance at hydrostatic pressure...
24936124 - Validation of datascope accutorr plus™ using british hypertension society (bhs) and a...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Tohoku journal of experimental medicine     Volume:  208     ISSN:  0040-8727     ISO Abbreviation:  Tohoku J. Exp. Med.     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-01-25     Completed Date:  2006-05-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417355     Medline TA:  Tohoku J Exp Med     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  117-22     Citation Subset:  IM    
Department of Cardiology, Kosuyolu Heart Education and Research Hospital, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hypertension / complications*
Hypertrophy, Left Ventricular / etiology*
Matrix Metalloproteinases / blood*
Middle Aged
Protease Inhibitors / adverse effects,  pharmacology
Risk Factors
Tissue Inhibitor of Metalloproteinases / adverse effects*
Ventricular Dysfunction / etiology*
Reg. No./Substance:
0/Protease Inhibitors; 0/Tissue Inhibitor of Metalloproteinases; EC 3.4.24.-/Matrix Metalloproteinases
Comment In:
Tohoku J Exp Med. 2006 Feb;208(2):93-7   [PMID:  16434829 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lactation and risk of endometrial cancer in Japan: a case-control study.
Next Document:  Smoking as a risk factor for visceral fat accumulation in Japanese men.